Cumulative Absolute Breast Cancer Risk for Young Women Treated for Hodgkin Lymphoma

Authors:
  • DHDeirdre Hill
    Deirdre Hill
  • MGMary Gospodarowicz
    Mary Gospodarowicz
  • FLFlora E. van Leeuwen
    Flora E. van Leeuwen
  • EHEric Holowaty
    Eric Holowaty
  • BGBengt Glimelius
    Bengt Glimelius
  • MAMichael Andersson
    Michael Andersson
  • EPEero Pukkala
    Eero Pukkala
  • CLCharles F. Lynch
    Charles F. Lynch
  • DPDavid Pee
    David Pee
  • SSSusan A. Smith
    Susan A. Smith

Abstract
Background: Many women develop breast cancer after treatment for Hodgkin lymphoma (HL) at a young age. We estimated this future risk, taking into account age and calendar year of HL diagnosis, HL treatment information, population breast cancer incidence rates, and competing causes of death. Methods: Relative risks of breast cancer for categories defined by radiation dose to the chest (0, 20–Results: Cumulative absolute risks of breast cancer increased with age at end of follow-up, time since HL diagnosis, and radiation dose. For an HL survivor who was treated at age 25 years with a chest radiation dose of at least 40 Gy without alkylating agents, estimated cumulative absolute risks of breast cancer by age 35, 45, and 55 years were 1.4% (95% confidence interval [CI] = 0.9% to 2.1%), 11.1% (95% CI = 7.4% to 16.3%), and 29.0% (95% CI = 20.2% to 40.1%), respectively. Cumulative absolute risks were lower in women treated with alkylating agents. Conclusions: Breast cancer projections varied considerably by type of HL therapy, time since HL diagnosis, and age at end of follow-up. These estimates are applicable to HL survivors treated with regimens of the past and can be used to counsel such patients and plan management and preventive strategies. Projections should be used with caution, however, in patients treated with more recent approaches, including limited-field radiotherapy and/or ovary-sparing chemotherapy.

This publication has 36 references indexed in Scilit: